RYR1 and neoplasm: The median overall survival among patients with low tumor CcO activity was 20 months (95% CI, 19.09 to 22.16), as compared with 6.54 months (95% CI, 3.2 to 8.08) among patients with high tumor CcO activity (P<0.0001 by the log-rank test) (Figure 3C).